

Revision date 24-Jan-2022

Version 4

Page 1/9

# Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name	Prevnar 13
Product Code(s)	PZ01454
Synonyms	Pneumococcal 13-Valent Conjugate Vaccine
Trade Name:	Prevnar 13; PREVENAR; PREVENAR 13
Chemical Family:	Not determined

# 1.2. Relevant identified uses of the substance or mixture and uses advised against

**Recommended Use** 

Pharmaceutical product

# 1.3. Details of the supplier of the safety data sheet

Pfizer Inc 235 East 42nd Street New York, New York 10017 1-800-879-3477 Pfizer Ireland Pharmaceuticals OSG Building Ringaskiddy, Co. Cork. Ireland +353 21 4378701

# 1.4. Emergency telephone number

Emergency Telephone E-mail address Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887 pfizer-MSDS@pfizer.com

# Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture GHS - Classification: Not classified as hazardous

2.2. Label elements Signal word	Not Classified
Hazard statements	Not classified in accordance with international standards for workplace safety.
<u>2.3. Other hazards</u> Other hazards	An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).
Note:	This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

# Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

# 3.1 Substances

Substances

Not applicable

# 3.2 Mixtures

### NonHazardous

Chemical name	Weight-%	REACH	EC No	Classification	Specific	M-Factor	M-Factor
		Registration		according to	concentration		(long-term)
		Number		Regulation	limit (SCL)		
				(EC) No.			
				1272/2008			
				[CLP]			
Water	*		231-791-2	No data	Not Listed	No data	No data
7732-18-5				available		available	available
Saline suspension	*		Not Listed	No data	Not Listed	No data	No data
MIXTURE				available		available	available
Succinate buffer	*		Not Listed	No data	Not Listed	No data	No data
NOT ASSIGNED				available		available	available
Pneumococcal	< 1		Not Listed	No data	Not Listed	No data	No data
13-valent Conjugate				available		available	available
NOT ASSIGNED							
Aluminum phosphate	*		232-056-9	No data	Not Listed	No data	No data
7784-30-7				available		available	available
Polysorbate 80	*		500-019-9	No data	Not Listed	No data	No data
9005-65-6				available		available	available

# Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

Chemical name	Oral LD50	Dermal LD50		Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Polysorbate 80 9005-65-6	34.5 mL/kg	No data available	No data available	No data available	No data available

# Additional information

# \* Proprietary

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

# Section 4: FIRST AID MEASURES

# 4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids.

	Consult a physician.		
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.		
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. In not induce vomiting unless directed by medical personnel. Seek medical attention immediately.		
4.2. Most important symptoms and	effects, both acute and delayed		
Most important symptoms and effects	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.		
4.3. Indication of any immediate me	edical attention and special treatment needed		
Note to physicians	None.		
Section 5: FIRE-FIGHTING N	IEASURES		
5.1. Extinguishing media			
Suitable Extinguishing Media	Dry chemical, CO2, alcohol-resistant foam or water spray.		
5.2. Special hazards arising from the second s	ne substance or mixture		
Specific hazards arising from the chemical	Fine particles (such as mists) may fuel fires/explosions.		
Hazardous combustion products	Formation of toxic gases is possible during heating or fire.		
5.3. Advice for firefighters			
Special protective equipment for fire-fighters	Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.		
Section 6: ACCIDENTAL RE	LEASE MEASURES		
6.1. Personal precautions, protecti	ve equipment and emergency procedures		
Personal precautions	Personnel involved in clean-up should wear appropriate personal protective equipment (see		
For emergency responders	Section 8). Minimize exposure. Use personal protection recommended in Section 8.		
6.2. Environmental precautions			
Environmental precautions	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.		
6.3. Methods and material for conta	ainment and cleaning up		
Methods for containment Methods for cleaning up	Prevent further leakage or spillage if safe to do so. Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clea spill area thoroughly.		
Prevention of secondary hazards	Clean contaminated objects and areas thoroughly observing environmental regulations.		
6.4. Reference to other sections			
Reference to other sections	See section 8 for more information. See section 13 for more information.		
Section 7: HANDLING AND 9			

# Section 7: HANDLING AND STORAGE

### 7.1. Precautions for safe handling

### Advice on safe handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

# 7.2. Conditions for safe storage, including any incompatibilities

**Storage Conditions** 

Store in a refrigerator. Store at 2 to 8 °C in properly labeled containers.

7.3. Specific end use(s)

Specific use(s)

Vaccine.

# Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1. Control parameters

### **Exposure Limits**

Refer to available public information for specific member state Occupational Exposure Limits.

Aluminum phosphate ACGIH TLV Spain	1 mg/m <sup>3</sup> 1 mg/m <sup>3</sup>
8.2. Exposure controls	
Engineering controls	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes.
Environmental exposure controls	No information available.
Personal protective equipment	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.
Eye/face protection	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).
Hand protection	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).
Skin and body protection	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
Respiratory protection	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).

### General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

# Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties	
Physical state	Ē
Color	١
Odor	١
Odor threshold	١
Molecular formula	Ν
Molecular weight	Ν

Property pH Melting point / freezing point Boiling point / boiling range Flash point Evaporation rate Flammability (solid, gas) Flammability Limit in Air Upper flammability limit:

Lower flammability limit:

Vapor pressure Vapor density Relative density Water solubility Solubility(ies) Partition coefficient Autoignition temperature Decomposition temperature Kinematic viscosity Dynamic viscosity Particle characteristics Particle Size Particle Size Particle Size Distribution Explosive properties Homogenous Suspension White No information available. No information available Mixture Mixture

<u>Values</u> No data available No data available

No information available No data available No data available

No data available

No data available

No data available No data available No data available No data available No data available No data available No data available No data available No data available No data available No data available

No information available No information available No information available

### 9.2. Other information

No information available

**9.2.1. Information with regard to physical hazard classes** No information available

### 9.2.2. Other safety characteristics

No information available

# Section 10: STABILITY AND REACTIVITY

10.1. Reactivity Reactivity 10.2. Chemical stability Stability Explosion data

No data available.

Stable under normal conditions.

Sensitivity to Mechanical Impac Sensitivity to Static Discharge	
10.3. Possibility of hazardous react	ions
Possibility of hazardous reactions	No information available.
10.4. Conditions to avoid	
Conditions to avoid	Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep away from heat sources and electrostatic discharge.
10.5. Incompatible materials Incompatible materials	As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products Hazardous decomposition products No data available.

# Section 11: TOXICOLOGICAL INFORMATION

# 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information:	The information included in this section describes the potential hazards of the individual ingredients
Short term	In the event of accidental injection, an allergic reaction may occur. If an allergic reaction occurs, the worker should be removed to the nearest emergency room and the appropriate therapy instituted.
Known Clinical Effects:	Based on clinical trials in humans, possible adverse effects following exposure to this compound may include: swelling, tenderness, fever, lack of appetite, irritability, sleepiness (somnolence), sleeplessness, allergic reaction, anaphylactic reactions, headache, nausea, diarrhea, and vomiting.

# Acute Toxicity: (Species, Route, End Point, Dose)

Pneumococcal 13-valent Conjugate Rat Subcutaneous Maximum Non-Lethal Dose .5 mL Non-human Primate Subcutaneous Maximum Non-Lethal Dose .5 mL Aluminum phosphate Mouse Oral LD 50 > 5000 mg/kg Rat Oral LD 50 > 2000 mg/kg Rabbit Dermal LD 50 > 4640 mg/kg Polysorbate 80 Rat Intravenous LD 50 1790 mg/kg

Mouse Oral LD 50 25 g/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
Polysorbate 80	= 34.5mL/kg(Rat)	-	-

**Acute Toxicity Comments:** 

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

# Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Pneumococcal 13-valent Conjugate

8 Week(s) Rat Subcutaneous \* 0.5 mL NOAEL None identified

13 Week(s) Rat Subcutaneous \* 0.5 mL NOAEL None identified

13 Week(s) Monkey Subcutaneous \* 0.5 mL NOAEL None identified

Repeated Dose Toxicity Comments: Pneumococcal 13-valent Conjugate: \* Notes: Doses are administrated 1 Dose/2 Weeks.

	city: (Duration, Species, Route, Dose, End Point, Effect(s))		
Pneumococcal 13-valent Conjugate Fertility and Embryonic Development teratogenic			
Carcinogenicity	None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.		
<b><u>11.2.</u></b> Information on other hazards 11.2.1. Endocrine disrupting prope Endocrine disrupting properties			
11.2.2. Other information Other adverse effects	No information available.		
Section 12: ECOLOGICAL IN	FORMATION		
Environmental Overview:	Environmental properties have not been investigated. Releases to the environment should be avoided.		
12.1. Toxicity			
No information available			
12.2. Persistence and degradability			
Persistence and degradability	No information available.		
12.3. Bioaccumulative potential			
<b>Bioaccumulation</b>	No information available.		
42.4 Mahiliku in anil			
12.4. Mobility in soil			
Mobility in soil	No information available.		
12.5. Results of PBT and vPvB assessment			
PBT and vPvB assessment			

# PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
Aluminum phosphate	PBT assessment does not apply

# 12.6. Endocrine disrupting properties

**Endocrine disrupting properties** No information available.

# 12.7. Other adverse effects

No information available.

# Section 13: DISPOSAL CONSIDERATIONS

# 13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

# Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

# Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-791-2
AICS	Present
Saline suspension	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
Succinate buffer	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
Pneumococcal 13-valent Conjugate	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
Aluminum phosphate	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	232-056-9
AICS	Present
Polysorbate 80	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	Not Listed
AICS	Present

**European Union** 

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

### Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

### Persistent Organic Pollutants

Not applicable

# Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory **EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances **AICS** - Australian Inventory of Chemical Substances

# 15.2. Chemical safety assessment

Chemical Safety Report No information available

# Section 16: OTHER INFORMATION

# Key or legend to abbreviations and acronyms used in the safety data sheet

Data Sources:	Pfizer proprietary drug development information. Publicly available toxicity information.
Reason for revision	Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information.
Revision date	24-Jan-2022
Prepared By	Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.